Germline mutations as a therapeutic target in breast cancer

10_JudithBalmana_wbs.jpgDr. Balmaña is the head of the Hereditary Cancer Genetics Group at Vall d’Hebron Institute of Oncology (VHIO), Barcelona, and an attending physician at the Breast Cancer Unit in the Medical Oncology Department at Hospital Vall D’Hebron, Barcelona.

This webinar will focus on 1) a summary of the biology of BRCA-associated breast tumours, which renders them sensitive to targeted therapies against DNA damage repair pathways, 2) an overview of the main studies providing evidence to treat these tumours with targeted drugs, and 3) challenges and mechanisms of resistance.